-
Sex and gender reporting advances in medicine Lancet Haematol. (IF 24.7) Pub Date : 2024-03-07 T, h, e, , L, a, n, c, e, t, , H, a, e, m, a, t, o, l, o, g, y
-
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-03-04 A, n, n, a, , C, a, n, d, o, n, i
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-03-04 Alexandre Bazinet MD, Prof Guillermo Garcia-Manero MD, Nicholas Short MD, Yesid Alvarado MD, Alex Bataller MD, Tareq Abuasab MD, Rabiul Islam MD, Kathryn Montalbano RN, Ghayas Issa MD, Abhishek Maiti MD, Musa Yilmaz MD, Prof Nitin Jain MD, Lucia Masarova MD, Prof Steven Kornblau MD, Prof Elias Jabbour MD, Guillermo Montalban-Bravo MD, Caitlin R Rausch PharmD, Sherry Pierce RN, Prof Courtney D DiNardo
Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727
-
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-03-01 Michiel Coppens MD, Prof Steven W Pipe MD, Prof Wolfgang Miesbach MD, Prof Jan Astermark MD, Michael Recht MD, Paul van der Valk MD, Bruce Ewenstein MD, Karen Pinachyan MD, Nicholas Galante PhD, Sandra Le Quellec MD, Prof Paul E Monahan MD, Prof Frank W G Leebeek MD, HOPE-B Investigators, Giancarlo Castaman, Shelley E Crary, Miguel Escobar, Esteban Gomez, Kristina M Haley, Cedric R J R Hermans, Peter
Etranacogene dezaparvovec, the first gene therapy approved for haemophilia B treatment, was shown to be superior to treatment with continuous prophylactic factor IX in terms of bleeding protection 18 months after gene therapy in a phase 3 trial. We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia
-
A thank you to our 2023 reviewers and update on inclusion and diversity commitments Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Editors of The Lancet Haematology
-
Health-care transition services for sickle cell disease in Brazil Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Jane S Hankins, Clarisse Lobo, Josefina A P Braga, Tarun Aurora, Kelly Pimenta, Maria Stella Figueiredo, Ana A Baumann
-
Gender composition and geographical representation of American Society of Hematology clinical practice guideline authors Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Jeremy W Jacobs, Amarilis A Martin, Laura D Stephens, Brian D Adkins, Jennifer S Woo, Deva Sharma, Allison P Wheeler, Raeshun T Glover, Jennifer C Yui, Shannon C Walker, Shazia S Khan, Garrett S Booth, Julie K Silver
-
Thank you to The Lancet Haematology's peer reviewers in 2023 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Lancet Haematology Editors
-
Celebrating our community: a call for essays and art Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Editors of The Lancet Haematology
-
Balancing the risks and benefits of CAR T-cell therapy Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Lancet Haematology
-
Clinical implications and insights from patient-reported outcome data in KarMMa-3 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Rajshekhar Chakraborty
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Prof Michel Delforge MD, Krina Patel MD, Laurie Eliason MPH, Devender Dhanda PhD, Ling Shi PhD, Shien Guo PhD, Thomas S Marshall PharmD, Prof Bertrand Arnulf MD, Prof Michele Cavo MD, Prof Ajay Nooka MD, Salomon Manier MD, Natalie Callander MD, Sergio Giralt MD, Prof Hermann Einsele MD, Prof Sikander Ailawadhi MD, Mihaela Popa McKiver MD PhD, Mark Cook MBChB PhD, Paula Rodríguez-Otero MD
Chimeric antigen receptor T-cell therapy idecabtagene vicleucel (ide-cel) showed significantly improved progression-free survival compared with standard regimens in adults with relapsed and refractory multiple myeloma who had received two to four previous regimens in the ongoing phase 3 KarMMa-3 trial (). This study analysed patient-reported outcomes (PROs), a KarMMa-3 secondary endpoint. In the randomised
-
Thrombotic complications of immune thrombocytopenic purpura Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Philip Qian MD, Abbey Willcox MBBS, Edward R Scheffer Cliff MBBS
-
-
-
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study Lancet Haematol. (IF 24.7) Pub Date : 2024-02-06 Phillip Scheinberg MD PhD, Carlo Finelli MD, Efreen H Montaňo-Figueroa MD, Carlos Vallejo MD, Lalita Norasetthada MD, Prof Rodrigo T Calado MD, Prof Mehmet Turgut MD, Prof Régis Peffault de Latour MD, Ulrike Kriemler-Krahn BA, Jens Haenig PhD, Joan Clark MSc, Prof Junho Jang MD
Antithymocyte globulin (ATG)-based immunosuppression is standard in front-line treatment for people with severe aplastic anaemia without a histocompatible donor or who are 40 years or older. However, ATG requires in-hospital administration, is associated with infusion-related toxicities and has limited availability worldwide. In this study, we investigated the activity and safety of an ATG-free regimen
-
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-02-06 Emma M Groarke
-
Correction to Lancet Haematol 2024; 11: e38–50 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-05
Abstract not available
-
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines Lancet Haematol. (IF 24.7) Pub Date : 2024-02-05 Hanny Al-Samkari MD, Prof Nadine Shehata MD MSc, Kelly Lang-Robertson MLIS, Paola Bianchi PhD, Andreas Glenthøj MD PhD, Prof Sujit Sheth MD, Prof Ellis J Neufeld MD PhD, Prof David C Rees MBBS, Satheesh Chonat MD, Kevin H M Kuo MD MSc, Prof Jennifer A Rothman MD, Prof Wilma Barcellini MD, Eduard J van Beers MD PhD, Dagmar Pospíšilová MD PhD, Prof Ami J Shah MD, Richard van Wijk PhD, Prof Bertil Glader
Pyruvate kinase (PK) deficiency is the most common cause of chronic congenital non-spherocytic haemolytic anaemia worldwide, with an estimated prevalence of one in 100 000 to one in 300 000 people. PK deficiency results in chronic haemolytic anaemia, with wide ranging and serious consequences affecting health, quality of life, and mortality. The goal of the International Guidelines for the Diagnosis
-
Lallindra Gooneratne—maintaining treatment flow amid crisis Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Ray Cavanaugh
Abstract not available
-
Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-02-02 Sarit Assouline
Abstract not available
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-02-02 Alex Bataller MD, Guillermo Montalban-Bravo MD, Alexandre Bazinet MD, Yesid Alvarado MD, Kelly Chien MD, Sangeetha Venugopal MD, Jo Ishizawa MD, Danielle Hammond MD, Mahesh Swaminathan MD, Koji Sasaki MD, Ghayas C Issa MD, Nicholas J Short MD, Lucia Masarova MD, Prof Naval G Daver MD, Prof Tapan M Kadia MD, Simona Colla PhD, Wei Qiao PhD, Prof Xuelin Huang PhD, Rashmi Kanagal-Shamanna MD, Stephany
Hypomethylating agents are approved in higher-riskmyelodysplastic syndromes. The combination of a hypomethylating agent with venetoclax is standard of care in acute myeloid leukaemia. We investigated the safety and activity of the first totally oral combination of decitabine plus cedazuridine and venetoclax in patients with higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia
-
Production and supply of blood products in Brazil Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Tony Kirby
Abstract not available
-
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Pauline Hägele, Paulina Staus, Raphael Scheible, Annette Uhlmann, Maximilian Heeg, Christian Klemann, Maria Elena Maccari, Henrike Ritterbusch, Martin Armstrong, Ioana Cutcutache, Katherine S Elliott, Horst von Bernuth, Timothy Ronan Leahy, Jörg Leyh, Dirk Holzinger, Kai Lehmberg, Peter Svec, Katja Masjosthusmann, Sophie Hambleton, Marcus Jakob, Thomas Wiesel
Background Lymphoproliferation and autoimmune cytopenias characterise autoimmune lymphoproliferative syndrome. Other conditions sharing these manifestations have been termed autoimmune lymphoproliferative syndrome-like diseases, although they are frequently more severe. The aim of this study was to define the genetic, clinical, and immunological features of these disorders to improve their diagnostic
-
Improving equity for people living with rare diseases Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30
Abstract not available
-
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Hideto Tamura
Abstract not available
-
Prospective characterisation of non-malignant, paediatric lymphoproliferative disease Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Troy R Torgerson
Abstract not available
-
Advancements in haemophilia A and health equity: is it time to redefine severity? Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Angela C Weyand, Lynn Malec, Steven W Pipe
Abstract not available
-
A treatise on clinical trials Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Talal Hilal
Abstract not available
-
Acute promyelocytic leukaemia in low-income and middle-income countries: a Brazilian experience Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Diego A Pereira-Martins, Isabel Weinhäuser, Juan L Coelho-Silva, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M Rego, Antonio R Lucena-Araujo
Abstract not available
-
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Elias K Mai, Hartmut Goldschmid, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Julia Krzykalla, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor W Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Christoph Mann, Niels Weinhold, Christof Scheid, Roland Schroers, Iris Zirpel
Background The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma. Methods GMMG-HD6 was a phase 3, randomised trial conducted at 43 main trial
-
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Valentin Lacombe, Jérome Hadjadj, Sophie Georgin-Lavialle, Christian Lavigne, Franck Geneviève, Olivier Kosmider
The presence of vacuoles in myeloid and erythroid progenitor cells in bone marrow aspirates is a key feature of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. The mere observation of vacuolated progenitor cells is not specific to VEXAS syndrome; in this Viewpoint, we point out the causes to be considered in this situation. Vacuoles, in particular, can be observed in individuals
-
When cancer disguises: small-cell lung cancer masquerading as HIV-associated lymphoma in leukaemic phase Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Shuhei Kurosawa, Yusuke Hamakawa, Yukihiro Yoshimura, Hiroyuki Hayashi, Tomonori Nakazato, Hiroaki Okamoto
Abstract not available
-
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-01-29 Elisabeth Schorb MD, Lisa Kristina Isbell MD, Andrea Kerkhoff MD, Prof Stephan Mathas MD, Friederike Braulke PhD, Gerlinde Egerer MD, Alexander Röth MD, Simon Schliffke MD, Peter Borchmann MD, Uta Brunnberg MD, Frank Kroschinsky MBA, Robert Möhle MD, Andreas Rank MD, Dominique Wellnitz MD, Benjamin Kasenda PhD, Lisa Pospiech MD, Julia Wendler MD, Florian Scherer MD, Prof Martina Deckert MD, Elina Henkes
Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) in older patients with PCNSL. MARTA was a prospective, single-arm, phase 2 study done at 15 research hospitals in Germany
-
Extending potentially curative options for older patients with PCNSL Lancet Haematol. (IF 24.7) Pub Date : 2024-01-29 Elizabeth H Phillips, Kate Cwynarski
Abstract not available
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-01-05 Pau Abrisqueta, Eva González-Barca, Carlos Panizo, José María Arguiñano Pérez, Fiona Miall, Mariana Bastos-Oreiro, Ana Triguero, Lalita Banerjee, Andrew McMillan, Erlene Seymour, Jamie Hirata, Jayson de Guzman, Sunil Sharma, Hyun Yong Jin, Lisa Musick, Catherine Diefenbach
Background Diffuse large B-cell lymphoma comprises nearly 30% of non-Hodgkin lymphoma cases and patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem-cell transplantation have few treatment options and poor prognoses. We aimed to determine whether the novel combination of polatuzumab vedotin in combination with rituximab and lenalidomide (Pola+R+Len) would provide
-
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation Lancet Haematol. (IF 24.7) Pub Date : 2024-01-03 Olaf Penack, Monia Marchetti, Mahmoud Aljurf, Mutlu Arat, Francesca Bonifazi, Rafael F Duarte, Sebastian Giebel, Hildegard Greinix, Mette D Hazenberg, Nicolaus Kröger, Stephan Mielke, Mohamad Mohty, Arnon Nagler, Jakob Passweg, Francesca Patriarca, Tapani Ruutu, Hélène Schoemans, Carlos Solano, Radovan Vrhovac, Daniel Wolff, Zinaida Peric
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic haematopoietic stem-cell transplantation (HSCT). In the last 3 years, there has been regulatory approval of new drugs and considerable change in clinical approaches to prophylaxis and management of GVHD. To standardise treatment approaches, the European Society for Blood and Marrow Transplantation
-
Correction to Lancet Haematol 2023; 10: e713–34 Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20
Abstract not available
-
Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Catherine Cargo, Elsa Bernard, Tumas Beinortas, Kelly L Bolton, Paul Glover, Helen Warren, Daniel Payne, Rukhsaar Ali, Alesia Khan, Mike Short, Suzan Van Hoppe, Alex Smith, Jan Taylor, Paul Evans, Elli Papaemmanuil, Simon Crouch
Background Somatic mutations are frequently reported in individuals with cytopenia but without a confirmed haematological diagnosis (clonal cytopenia of undetermined significance; CCUS). These patients have an increased risk of progression to a myeloid malignancy and worse overall survival than those with no such mutations. To date, studies have been limited by retrospective analysis or small patient
-
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-12-21 Domenico Russo, Michael Schmitt, Sylvain Pilorge, Matthias Stelljes, Toshiro Kawakita, Valerie L Teal, Barbara Haber, Charlene Bopp, Sanjeet S Dadwal, Cyrus Badshah
Background In a pivotal phase 3 trial of cytomegalovirus prophylaxis with letermovir for up to 100 days after allogeneic haematopoietic stem-cell transplantation (HSCT), 12% of participants developed clinically significant cytomegalovirus infection after letermovir was discontinued. We aimed to evaluate the efficacy and safety of extending the duration of letermovir prophylaxis for clinically significant
-
Extended duration of letermovir prophylaxis: how long is long enough? Lancet Haematol. (IF 24.7) Pub Date : 2023-12-21 Abby P Douglas, Monica A Slavin
Abstract not available
-
The dawn of the CRISPR/Cas9 gene therapy era Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20
Abstract not available
-
Oral decitabine plus cedazuridine versus intravenous decitabine Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Theo de Witte
Abstract not available
-
Predicting the progression of patients with CCUS to myeloid neoplasia Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Emma M Groarke
Abstract not available
-
Changing the paradigm of AML care in India Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Amitabh Singh, Ankur Jain, Heena Tabbassum, Fouzia Siraj, Bhavika Rishi, Aroonima Misra
Abstract not available
-
Lucrèce Delicat-Loembet: offering hope to young people with sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Tony Kirby
Abstract not available
-
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT? Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Patrice Chevallier
Abstract not available
-
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT? Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Nicolas Boissel
Abstract not available
-
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aref Al-Kali, H Joachim Deeg, Prapti A Patel, Mitchell Sabloff, Mary-Margaret Keating, Nancy Zhu, Nashat Y Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy E DeZern, Casey L O’Connell, Gail J Roboz, Lambert Busque, Michael R Savona
Background The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia are available in parenteral form. Oral therapy with similar exposure for these diseases would offer potential treatment benefits. We aimed to compare the safety and pharmacokinetics of oral decitabine plus the cytidine deaminase inhibitor cedazuridine
-
A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Laure Joseph, Marine Driessen
Sickle cell disease is a major public health concern due to its prevalence and associated morbidities. In high-income countries, diagnosis and treatment advancements have extended patient's lives and enabled women to embrace motherhood. Although the provision of care in specialist centres has reduced maternal–fetal complication rates, the mortality rate among pregnant women with sickle cell disease
-
2023 ASH Annual Meeting Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Emma Cookson
Abstract not available
-
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Lancet Haematol. (IF 24.7) Pub Date : 2023-12-05 Maximilian Stahl, Amy E DeZern
Abstract not available
-
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-12-05 Amer M Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan, Stef Meers, Vinod Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Julie Niolat, Pedro Marques Ramos, Hans D Menssen, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
Background Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the efficacy and safety of sabatolimab plus hypomethylating agent with placebo plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes.
-
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group Lancet Haematol. (IF 24.7) Pub Date : 2023-12-04 Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, Markus Ditschkowski, Nico Gagelmann, Martin Griesshammer, Vikas Gupta, Nada Hamad, Claire Harrison, Juan Carlos Hernandez-Boluda, Steffen Koschmieder, Tania Jain, John Mascarenhas, Ruben Mesa, Uday R Popat, Francesco Passamonti, Nicola Polverelli, Alessandro Rambaldi, Marie Robin, Rachel B Salit, Giovanni Barosi
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the management of patients with myelofibrosis. To inform patients’ optimal care, we updated the 2015 guidelines on indications for and management of allogeneic haematopoietic stem-cell transplantation (HSCT) with the support of the European Society for Blood and Marrow Transplantation
-
Improving haematological care for adolescents Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27
Abstract not available
-
Use of darbepoetin alfa in haemolytic disease of the fetus and newborn Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27 Ravi M Patel, Robin Ohls
Abstract not available
-
Life after sickle cell disease, is it really uhuru? Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27 Lydia H Pecker, Adeseye M Akinsete, C Patrick Carroll, Sophie Lanzkron, Kevin H M Kuo, Monica Hulbert, Elizabeth Stenger, Deepika S Darbari
Abstract not available
-
Assessing authorship of clinical practice guidelines Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27 Jeremy W Jacobs, Brian D Adkins, Deva Sharma, Allison P Wheeler, Laura D Stephens, Jennifer S Woo, Shazia S Khan, Garrett S Booth
Abstract not available
-
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27 Jong Wook Lee, Morag Griffin, Jin Seok Kim, Lily Wong Lee Lee, Caroline Piatek, Jun-ichi Nishimura, Cynthia Carrillo Infante, Deepak Jain, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Risitano, Austin G Kulasekararaj
Background Symptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with C5 inhibitors (ravulizumab or eculizumab). The aim of this study was to assess the efficacy and safety of danicopan (ALXN2040), an investigational, first-in-class, oral complement factor D inhibitor, as add-on therapy to ravulizumab or
-
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn who are treated with intrauterine transfusions in the Netherlands: an open-label, single-centre, phase 2, randomised, controlled trial Lancet Haematol. (IF 24.7) Pub Date : 2023-11-27 Isabelle M C Ree, Masja de Haas, Nan van Geloven, Sandra E Juul, Derek de Winter, E J T Verweij, Dick Oepkes, Johanna G van der Bom, Enrico Lopriore
Background Up to 88% of infants with haemolytic disease of the fetus and newborn who are treated with intrauterine transfusions require erythrocyte transfusions after birth. We aimed to investigate the effect of darbepoetin alfa on the prevention of postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Methods We conducted an open-label, single-centre, phase 2 randomised controlled